ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NEOG vs NTLA // FORWARD P/E MULTIPLE

Neogen Corporation (NASDAQ) VS. Intellia Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: NEOG 7 — NTLA 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NEOG VS. NTLA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NEOG NTLA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 46.90% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -0.60% -35.00% +34.40 NEOG /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 3.11% -21.35% +24.46 NEOG /fcf-yield <GO>
Operating Margin -2.50% -60.00% +57.50 NEOG /operating-margins <GO>
Net Profit Margin -0.90% -60.00% +59.10 NEOG /net-margins <GO>
Revenue Growth (YoY) -2.70% 16.90% -19.60 NTLA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.45 1.17 +0.28 NEOG /balance-sheet <GO>
Piotroski F-Score Quality 7/9 4/9 +3.00 NEOG /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.3 53.4 -8.19 NTLA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.68B $1.85B $822.6M NEOG /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NEOG REV NTLA REV NEOG GROSS % NTLA GROSS % NEOG FCF NTLA FCF
FY 2025 $870.4M $67.7M 46.9% — $83.2M -$395.9M
FY 2024 $894.7M $57.9M 47.1% — $58.2M -$354.7M
FY 2023 $924.2M $36.3M — — $35.3M -$394.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NEOG // BETA —
NTLA // BETA —